公开(公告)号：US20240408020A1

公开(公告)日：2024-12-12

申请号：US18815955

申请日：2024-08-27

Applicant: Translate Bio, Inc.

Inventor： Braydon Charles Guild ,  Michael Heartlein ,  Frank DeRosa ,  Jerry Chi Zhang

IPC: A61K9/19 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K38/45 ,  A61K38/46 ,  A61K38/47 ,  A61K38/50 ,  C07C323/25 ,  C07C323/27 ,  C07C323/44 ,  C07D233/64 ,  C07J41/00 ,  C07J43/00 ,  C12N15/88

Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

公开(公告)号：US20240299489A9

公开(公告)日：2024-09-12

申请号：US17449679

申请日：2021-10-01

Applicant: Translate Bio, Inc.

Inventor： Michael Heartlein ,  Frank DeRosa ,  Alan Kimura ,  Jonathan Abysalh ,  Anusha Dias ,  Shrirang Karve ,  Zarna Patel

IPC: A61K38/17 ,  A61K9/00 ,  A61K9/127 ,  A61K48/00 ,  A61P11/12

CPC classification number: A61K38/1709 ,  A61K9/0078 ,  A61K9/127 ,  A61K48/0075 ,  A61P11/12 ,  C12N15/88

Abstract: The present invention provides, among other things, methods of treating cystic fibrosis, comprising a step of administering to a subject in need of treatment a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, wherein the mRNA encoding the CFTR protein comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 1, wherein the mRNA is at a concentration of at least 0.4 mg/mL, and wherein the step of administering comprises inhalation.

公开(公告)号：US12076438B2

公开(公告)日：2024-09-03

申请号：US17066919

申请日：2020-10-09

Applicant: Translate Bio, Inc.

Inventor： Christian Cobaugh ,  Richard Wooster ,  Frank DeRosa ,  Anusha Dias ,  Shrirang Karve

IPC: A61K9/127 ,  A61K9/00 ,  A61K38/17 ,  A61K38/19 ,  A61K38/20 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K9/007 ,  A61K9/0078 ,  A61K38/1709 ,  A61K38/19 ,  A61K38/193 ,  A61K38/208 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention provides, among other things, methods and compositions for cancer treatment. The methods and compositions disclosed herein are particularly effective in reducing the size/volume of a tumor and inhibiting tumor growth.

公开(公告)号：US11964051B2

公开(公告)日：2024-04-23

申请号：US17054886

申请日：2019-05-15

Applicant: Translate Bio, Inc.

Inventor： Frank DeRosa ,  Shrirang Karve ,  Yi Zhang ,  Michael Heartlein

IPC: A61K9/127 ,  A61K9/00 ,  A61K38/18 ,  C07H13/06

CPC classification number: A61K9/1272 ,  A61K9/0019 ,  A61K9/0078 ,  A61K38/1816 ,  C07H13/06

Abstract: Disclosed are cationic lipids which are compounds of Formula (I′). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

公开(公告)号：US11884692B2

公开(公告)日：2024-01-30

申请号：US17811022

申请日：2022-07-06

Applicant: Translate Bio, Inc.

Inventor： Frank DeRosa ,  Anusha Dias ,  Michael Heartlein ,  Shrirang Karve

IPC: C07H1/06 ,  C07H21/00 ,  C12N15/10 ,  C07H21/02

CPC classification number: C07H1/06 ,  C07H21/00 ,  C07H21/02 ,  C12N15/1017

Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.

公开(公告)号：US20240018514A1

公开(公告)日：2024-01-18

申请号：US18065952

申请日：2022-12-14

Applicant: Translate Bio, Inc.

Inventor： Jonathan Abysalh ,  Daniel Crawford ,  Frank DeRosa ,  Anusha Dias ,  Michael Heartlein

IPC: C12N15/10 ,  C12P19/34 ,  C12N9/12 ,  G01N27/447

CPC classification number: C12N15/1096 ,  C12Y207/07006 ,  G01N27/44778 ,  C12N9/1247 ,  C12N15/1068 ,  C12P19/34

Abstract: The present invention provides methods for large-scale production of a composition enriched for full-length mRNA molecules using an SP6 RNA polymerase and compositions produced using such methods and uses thereof.

公开(公告)号：US20230302039A1

公开(公告)日：2023-09-28

申请号：US18049210

申请日：2022-10-24

Applicant: Translate Bio, Inc. ,  Ethris GmbH

Inventor： Michael Heartlein ,  Braydon Charles Guild ,  Frank DeRosa ,  Carsten Rudolph ,  Christian Plank ,  Lianne Smith

IPC: A61K31/713 ,  A61K31/7105 ,  A61K48/00 ,  A61K31/7115 ,  A61K9/00 ,  A61K9/51 ,  A61K47/69 ,  C07K14/705 ,  A61K9/127 ,  C12N9/14

CPC classification number: A61K31/713 ,  A61K31/7105 ,  A61K48/005 ,  A61K31/7115 ,  A61K9/0078 ,  A61K9/5123 ,  A61K47/6935 ,  C07K14/705 ,  A61K9/0073 ,  A61K9/1271 ,  C12N9/14 ,  C12N15/63

Abstract: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.

公开(公告)号：US20220411781A1

公开(公告)日：2022-12-29

申请号：US17835725

申请日：2022-06-08

Applicant: Translate Bio, Inc.

Inventor： Frank DeRosa ,  Anusha Dias ,  Michael Heartlein ,  Shrirang Karve

IPC: C12N15/10 ,  C07H21/02

Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.

公开(公告)号：US20220402958A1

公开(公告)日：2022-12-22

申请号：US17811022

申请日：2022-07-06

Applicant: Translate Bio, Inc.

Inventor： Frank DeRosa ,  Anusha Dias ,  Michael Heartlein ,  Shrirang Karve

IPC: C07H1/06 ,  C07H21/00 ,  C12N15/10 ,  C07H21/02

Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.

公开(公告)号：US20220395459A1

公开(公告)日：2022-12-15

申请号：US17737712

申请日：2022-05-05

Applicant: Translate Bio, Inc.

Inventor： Shrirang Karve ,  Zarna Patel ,  Yi Zhang ,  Ashish Sarode ,  Rebecca L. Goldman ,  Frank DeRosa ,  Michael Heartlein

IPC: A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K31/7105

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.